首页 › 基金 › Atle Fund Management AB › JBIO

Atle Fund Management AB 对 JBIO 的持仓历史

JADE BIOSCIENCES INC · 医疗保健

Atle Fund Management AB 在 Q2 2026 的 13F 申报中披露持有 JBIO(JADE BIOSCIENCES INC)88,556 股,市值约 US$2.0M,约占其申报组合的 0.53%,在其申报持仓中市值排名第 39 位。 Atle Fund Management AB 于 Q2 2026 首次申报该持仓。

最新持仓 (Q2 2026)88.56K 股
申报持仓市值$1.97M
组合权重0.53%
首次申报Q2 2026
最近变动新进
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

Atle Fund Management AB 对 JBIO 的持仓演变

Atle Fund Management AB 于 Q2 2026 首次披露 JBIO 持仓:88,556 股(约 US$2.0M)。

逐季持仓明细

季度股数金额变化
Q2 2026 88.56K $1.97M 新进

关于 JBIO 与 13F 数据

JBIO(JADE BIOSCIENCES INC)属于医疗保健行业。我们追踪的基金中还有 106 只申报持有 JBIO,申报仓位最大的包括:Fairmount Funds Management LLC (US$101.2M), RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 JBIO 的基金

查看 JBIO 的全部基金持有人 →

常见问题

How long has Atle Fund Management AB held JBIO?

Atle Fund Management AB has disclosed JBIO holdings in 1 of the last 1 reported quarters, going back to Q2 2026.

What is Atle Fund Management AB's current position in JBIO?

As of Q2 2026, Atle Fund Management AB holds 88.56K shares of JBIO (JADE BIOSCIENCES INC), valued at $1.97M, representing 0.53% of its reported portfolio and ranking #39.

Has Atle Fund Management AB been buying or selling JBIO?

In the latest 13F filing (Q2 2026), Atle Fund Management AB newly opened its position in JBIO.

Which other funds hold JBIO?

Other major institutional holders of JBIO include Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, among 106 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.